Comparison of 3 protocols for treatment after induction of remission in dogs with lymphoma

Journal of Veterinary Internal Medicine

Volumn 21, Issue 6, 2007, Pages 1364-1373

  Rassnick, Kenneth M ^a   McEntee, Margaret C ^a   Erb, Hollis N ^a   Burke, Blaise P ^a,b   Balkman, Cheryl E ^a   Flory, Andrea B ^a   Kiselow, Michael A ^a   Autio, Karoliina ^a   Gieger, Tracy L ^a  

^a Department of Obstetrics Gynecology   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Cancer; Chemotherapy; Consolidation; Oncology; Radiation therapy

Indexed keywords

ANTINEOPLASTIC AGENT;

ANIMAL; ANIMAL DISEASE; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; DOG; DOG DISEASE; LYMPHOMA; REMISSION;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DOG DISEASES; DOGS; LYMPHOMA; REMISSION INDUCTION;

ANIMALIA; CANIS FAMILIARIS;

EID: 37349077577     PISSN: 08916640     EISSN: None     Source Type: Journal    
DOI: 10.1892/07-057.1     Document Type: Article

References (30)

1. Stone MS, Goldstein MA, Cotter SM. Comparison of two protocols for induction of remission in dogs with lymphoma. J Am Anim Hosp Assoc 1991;27:315-321.
2. Keller ET, MacEwen EG, Rosenthal RC, et al. Evaluation of prognostic factors and sequential combination chemotherapy for canine lymphoma. J Vet Intern Med 1993;7:289-295.
3. Myers NC, Moore AS, Rand WM, et al. Evaluation of a multidrug chemotherapy protocol (ACOPA-II) in dogs with lymphoma. J Vet Intern Med 1997;11:333-339.
4. Zemann BI, Moore AS, Rand WM, et al. A combination chemotherapy protocol (VELCAP-L) for dogs with lymphoma. J Vet Intern Med 1998;12:465-170.
5. Moore AS, Cotter SM, Rand WM, et al. Evaluation of a discontinuous treatment protocol (VELCAP-S) for canine lymphoma. J Vet Intern Med 2001;15:348-354.
6. Garrett LD, Thamm DH, Chun R, et al. Evaluation of a 6-month chemotherapy protocol with no maintenance therapy for dogs with lymphoma. J Vet Intern Med 2002;16:704-709.
7. MacDonald VS, Thamm DH, Kurzman ID, et al. Does L-asparaginase influence efficacy or toxicity when added to a standard CHOP protocol for dogs with lymphoma? J Vet Intern Med 2005;19:732-736.
8. Simon D, Nolte I, Eberle N, et al. Treatment of dogs with lymphoma using a 12-week, maintenance-free combination chemotherapy protocol. J Vet Intern Med 2006;20:948-954.
9. Siedlecki CT, Kass PH, Jakubiak MJ, et al. Evaluation of an actinomycin-D-containing combination chemotherapy protocol with extended maintenance therapy for canine lymphoma. Can Vet J 2006;47:52-59.
10. Frimberger AE, Moore AS, Rassnick KM, et al. A combination chemotherapy protocol with dose intensification and autologous bone marrow transplant (VELCAP-HDC) for canine lymphoma. J Vet Intern Med 2006;20:355-364.
11. Chun R, Garrett LD, Vail DM. Evaluation of a high-dose chemotherapy protocol with no maintenance therapy for dogs with lymphoma. J Vet Intern Med 2000;14:120-124.
12. Jeffreys AB, Knapp DW, Carlton WW, et al. Influence of asparaginase on a combination chemotherapy protocol for canine multicentric lymphoma. J Am Anim Hosp Assoc 2005;41: 221-226.
13. Jeglum KA. Chemoimmunotherapy of canine lymphoma with adjuvant canine monoclonal antibody 231. Vet Clin North Am Small Anim Pract 1996;26:73-85.
14. Williams LE, Johnson JL, Hauck ML, et al. Chemotherapy followed by half-body radiation therapy for canine lymphoma. J Vet Intern Med 2004;18:703-709.
15. Gustafson NR, Lana SE, Mayer MN, et al. A preliminary assessment of whole-body radiotherapy interposed within a chemotherapy protocol for canine lymphoma. Vet Comp Oncol 2005;2:125-131.
16. Axiak SM, Carreras JK, Hahn KA, et al. Hematologic changes associated with half-body irradiation in dogs with lymphoma. J Vet Intern Med 2006;20:1398-1401.
17. Morrison-Collister KE, Rassnick KM, Northrup NC, et al. A combination chemotherapy protocol with MOPP and CCNU consolidation (Tufts VELCAP-SC) for the treatment of canine lymphoma. Vet Compar Oncol 2003;1:180-190.
18. Brookmeyer R, Crowley JJ. A confidence interval for the median survival time. Biometrics 1982;38:29-41.
19. Owen LN. TNM Classification of Tumors in Domestic Animals. Geneva, Switzerland: World Health Organization 1980.
20. Veterinary co-operative oncology group common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.0. Vet Compar Oncol 2004;2:195-213.
21. Diehl L, Perry D. A comparison of randomized concurrent control groups with matched historical control groups: Are historical controls valid? J Clin Oncol 1986;4:1114-1120.
22. Moore AS, London CA, Wood CA, et al. Lomustine (CCNU) for the treatment of resistant lymphoma in dogs. J Vet Intern Med 1999;13:395-398.
23. Rassnick KM, Mauldin GE, al Sarraf R, et al. MOPP chemotherapy for treatment of resistant lymphoma in dogs: A retrospective study of 117 cases (1989-2000). J Vet Intern Med 2002;16:576-580.
24. Laing EJ, Fitzpatrick PJ, Binnington AG, et al. Half-body radiotherapy in the treatment of canine lymphoma. J Vet Intern Med 1989;3:102-108.
25. Lana SE, Jackson TL, Burnett RC, et al. Utility of polymerase chain reaction for analysis of antigen receptor rearrangement in staging and predicting prognosis in dogs with lymphoma. J Vet Intern Med 2006;20:329-334.
26. Calzolari C, Gentilini F, Agnoli C, et al. PCR assessment of minimal residual disease in 8 lymphoma-affected dogs. Vet Res Commun 2006;30(Suppl 1):285-288.
27. Skipper HE, Schabel FM Jr, Wilcox WS. Experimental evaluation of potential anticancer agents. XIII. On the criteria and kinetics associated with "curability" of experimental leukemia. Cancer Chemother Rep 1964;35:1-111.
28. Fitzpatrick PJ, Rider WD. Half body radiotherapy. Int J Radiat Oncol Biol Phys 1976;1:197-207.
29. Rassnick KM, Moore AS, Williams LE, et al. Treatment of canine mast cell tumors with CCNU (lomustine). J Vet Intern Med 1999;13:601-605.
30. Kelsey CR, Marks LB. Somnolence syndrome after focal radiation therapy to the pineal region: Case report and review of the literature. J Neurooncol 2006;78:153-156.